The potential role of ERG as a cancer driver and the high incidence of the TMPRSS2-ERG gene fusion in prostate cancer have catapulted this protein into the forefront of new targets for therapeutic intervention. This evidence concerns the gene TMPRSS2 and prostate carcinoma.